Lantheus Holdings, Inc. (BIT:1LNTH)

Market Cap	3.14B
Revenue (ttm)	1.29B
Net Income (ttm)	230.76M
Shares Out	n/a
EPS (ttm)	3.21
PE Ratio	13.60
Forward PE	9.72
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	9
Open	46.45
Previous Close	46.45
Day's Range	46.45 - 46.45
52-Week Range	44.87 - 62.82
Beta	n/a
RSI	n/a
Earnings Date	Jul 31, 2025

About Ligand Pharmaceuticals

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked o...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1956
• Employees: 808
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1LNTH

Financial Performance

In 2024, Lantheus Holdings's revenue was $1.53 billion, an increase of 18.32% compared to the previous year's $1.30 billion. Earnings were $312.44 million, a decrease of -4.35%.